Market Spotlight: Ischemic Stroke
Market Spotlight: Ischemic Stroke
$1,318.00
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
Key Takeaways
- Datamonitor Healthcare estimates that in 2018, there were approximately 82.3 million prevalent cases of ischemic stroke worldwide, and forecasts that number to increase to 88.0 million prevalent cases by 2027.
- The approved drugs in the ischemic stroke space focus on a wide variety of targets. Most approved drugs are administered orally, with two drugs administered intravenously and one drug administered subcutaneously.
- The majority of industry-sponsored drugs in active clinical development for ischemic stroke are in Phase II. Therapies in active clinical development for ischemic stroke focus on a wide variety of targets and include small molecules, peptides, and cell-based therapies.
- High-impact upcoming events for drugs in the ischemic stroke space comprise topline Phase II trial results for Trans Sodium Crocetinate, TMS-007, and S-005151, topline Phase IIb trial results for ReN001, topline Phase III trial results for Cirara, and an expected supplemental CHMP opinion for Brilinta.
- The overall likelihood of approval of a Phase I ischemic stroke asset is 0.8%, and the average probability a drug advances from Phase III is 11.1%. Drugs, on average, take 13.3 years from Phase I to approval, compared to 9.8 years in the overall neurology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for stroke have been in the early and midphases of development, with 70% of trials in Phase I–II, and 30% in Phase III–IV.
- The US has a substantial lead in the number of stroke clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the stroke space is dominated by completed trials. Roche has the highest number of completed clinical trials for stroke, with 21 trials.
- Roche leads industry sponsors with the highest overall number of clinical trials for stroke, followed by Boehringer Ingelheim and Daiichi Sankyo
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Acute treatment of ischemic stroke
11 Long-term treatments
11 Palliative care
12 EPIDEMIOLOGY
15 MARKETED DRUGS
18 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 SB623 for Ischemic Stroke (September 14, 2020)
26 DM199 for Ischemic Stroke (May 13, 2020)
28 NA-1 for Ischemic Stroke (February 20, 2020)
31 KEY UPCOMING EVENTS
32 KEY REGULATORY EVENTS
32 Further Horizons For Direct Oral Anticoagulants
32 NDAs And More: Recent Submissions For FDA Approval
32 Medtronic Wins In England’s NICE Decision On Implantable Monitors For Stroke Patients; Biotronik And Abbott Lose
33 PROBABILITY OF SUCCESS
34 REVENUE OPPORTUNITY
35 CLINICAL TRIAL LANDSCAPE
36 Sponsors by status
37 Sponsors by phase
38 Recent events
39 BIBLIOGRAPHY
39 Prescription information
40 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of ischemic stroke, 2018–27
18 Figure 2: Overview of pipeline drugs for ischemic stroke in the US
19 Figure 3: Pipeline drugs for ischemic stroke, by company
19 Figure 4: Pipeline drugs for ischemic stroke, by drug type
19 Figure 5: Pipeline drugs for ischemic stroke, by classification
26 Figure 6: SB623 for Ischemic Stroke (September 14, 2020): Phase IIb – ACTIsSIMA
28 Figure 7: DM199 for Ischemic Stroke (May 13, 2020): Phase II – ReMEDy
30 Figure 8: NA-1 for Ischemic Stroke (February 20, 2020): Phase III – ESCAPE-NA1
31 Figure 9: Key upcoming events in ischemic stroke
33 Figure 10: Probability of success in the ischemic stroke pipeline
35 Figure 11: Clinical trials in stroke
35 Figure 12: Top 10 drugs for clinical trials in stroke
36 Figure 13: Top 10 companies for clinical trials in stroke
36 Figure 14: Trial locations in stroke
37 Figure 15: Stroke trials status
38 Figure 16: Stroke trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of ischemic stroke, 2018–27
16 Table 2: Marketed drugs for ischemic stroke
21 Table 3: Pipeline drugs for ischemic stroke in the US
25 Table 4: SB623 for Ischemic Stroke (September 14, 2020)
27 Table 5: DM199 for Ischemic Stroke (May 13, 2020)
29 Table 6: NA-1 for Ischemic Stroke (February 20, 2020)
34 Table 7: Historical global sales, by drug ($m), 2015–19
34 Table 8: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Amyotrophic Lateral Sclerosis (ALS) 
Sign up to the